A Phase 4 interventional study of acoltremon 0.003% in Dry Eye, Dry Eyes Chronic and Dry Eye Syndromes, sponsored by Southern College of Optometry. Not yet recruiting. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Southern College of Optometry · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing acoltremon in Dry Eye Syndromes — 9 open to participants now, 9 under way, none of them phase 3. acoltremon · Dry Eye Syndromes.
Among the 17 studies testing acoltremon in Dry Eye Syndromes, this one is the 6th largest by planned enrollment, is one of 5 that started in 2025, is one of 9 in phase 4, and was the 9th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →9 of the 17 studies testing acoltremon in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Southern College of Optometry · Sites in United States
Ages 18–75
University of California, Berkeley · Sites in United States
Ages 18+
Southern College of Optometry · Sites in United States
Ages 18+
Eye Research Associates, LLC
Ages 18+
By country, each count listing its studies:
acoltremon: first FDA approval 2025 (TRYPTYR). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 9
First in 2017; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 100 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 17 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 9 most frequent:
Southern College of Optometry is the lead sponsor of 18 studies on the registry; 10 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Southern College of Optometry has 8 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
6 of the studies testing acoltremon in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07848373Eye Research Associates, LLCContact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003% | 2027-02-14 |
| NCT07732010NYU Langone HealthTRYPTYR as a Treatment for Patients With Dry Eye Disease (DED) | 2027-04-20 |
| NCT07888452University of California, BerkeleyCooling Eyedrops for Dry Eye | 2027-05 |
| NCT07849803University of South FloridaEffect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies testing acoltremon in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%.
Hypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.
This prospective, single-masked (participant), single-armed, study will determine how participants who are being treated with Xiidra respond to acoltremon 0.003%. Pre- to post-drop Schirmer's test scores at Day 1 will be the primary outcome. Some studies found the Day 1 mean differences for pre- to post-drop Schirmer's test score was 8.9, and the 28 Day mean differences for pre- to post-drop Schirmer's test score was 10.6 0.58 mm. If one assumes a clinically meaningful difference of 3 units (SD = 0.58; α of 0.05 and power of 80%), a total of 3 subjects will be needed to determine if there is a significant change in pre- to post-drop Schirmer's test scores. SPEED questionnaire at Days 14 and 28 will be the secondary outcomes. SPEED questionnaire scores of 2.2, 5.0, 6.6, and 9.9 corresponded to having asymptomatic, mild, moderate, and severe dry eye symptoms, and as such a 3 unit change will be considered to be a clinically meaningful difference.11 Asiedu et al. found that the typical subject with moderate dry eye has a mean SD SPEED score of 6.6 , which is the target symptoms severity level of this study.11 If one assumes a clinically meaningful difference of 3 units (SD = 4.1; α of 0.05 and power of 80%), a total of 17 subjects will be needed to determine if there is a significant change in SPEED scores at day 14 or 28. Exploratory outcomes include Likert survey questions; thus, the overall sample size will be inflated to 100 participants to help ensure that representative survey responses are obtained from the participants included in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.
Drug: acoltremon 0.003%
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.
Change between pre- and post-drop in unanesthetized Schirmer test score on Day 1
The Schirmer's strip wetting time/quantity will be measured before and after the drop with quicker and more wetting me considered better.
Time frame: 1 day
Change in standardized speed scores
The standardized speed scores will be measured to determine change from baseline to 28 days with lower scores being better.
Time frame: 28 days
2 week change in standardized speed scores
The standardized speed scores will be measured to determine change from baseline to 14 days with lower scores being better.
Time frame: 14 days
No study locations are listed for this record.
Start is estimated for Dec 2025; primary completion for Apr 2026, 4 months later.
Of 84 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoltremon
Southern College of Optometry